<DOC>
	<DOC>NCT01512758</DOC>
	<brief_summary>This is an open-label, multicenter, phase 1 study of alisertib in East Asian patients (eg, patients from countries including but not limited to Singapore, Hong Kong, Taiwan, and South Korea) with either relapsed or refractory advanced solid tumors or lymphomas for which no effective standard treatment is available.</brief_summary>
	<brief_title>A Study of Alisertib (MLN8237) in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Male or female East Asian patients 18 years or older Histologically or cytologically confirmed metastatic and/or advanced solid tumors or lymphomas for which no effective standard treatment is available Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Expected survival longer than 3 months from study enrollment Radiographically or clinically evaluable tumor Female patients who are post menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of contraception through 30 days after the last dose of study drug or agree to abstain from heterosexual intercourse Male patients who agree to practice effective barrier contraception through 6 months after the last dose of alisertib or agree to abstain from heterosexual intercourse Voluntary written consent Female patients who are lactating or pregnant Treatment with any investigational products, systemic antineoplastic treatment, or antineoplastic treatment with glucocorticoids within 21 days preceding the first dose of alisertib Treatment with nitrosoureas, mitomycin C, rituximab, alemtuzumab, or other unconjugated antibody treatment within 42 days (21 days if clear evidence of progressive disease) Medical conditions requiring daily, chronic, or regular use of proton pump inhibitors or H2receptor antagonists Treatment with radioimmunoconjugates such as ibritumomab tiuxetan or tositumomab within 56 days preceding first alisertib dose Major surgery within the 14 days preceding the first dose of alisertib Lifethreatening or uncontrolled medical illness unrelated to cancer Known gastrointestinal (GI) disease or procedures that could interfere with the oral absorption or tolerance of alisertib Inability to swallow capsules Inadequate bone marrow or other organ function Diagnosed or treated for another malignancy within 2 years of first dose of alisertib, or previously diagnosed with another malignancy and have any radiographic or biochemical marker evidence of active disease. In the case of prior prostate cancer treated with radiotherapy, the prostate specific antigen (PSA) may be detectable, but must be &lt; 1 ng/mL. Patients with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy of any type are not excluded Other severe acute or chronic medical or psychiatric conditions, including uncontrolled diabetes, or laboratory abnormality Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface antigenpositive status, or known or suspected active hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>East Asian Patients</keyword>
	<keyword>Advanced solid tumors</keyword>
	<keyword>Lymphomas</keyword>
	<keyword>MLN8237</keyword>
	<keyword>Alisertib</keyword>
	<keyword>Aurora A Kinase Inhibitor</keyword>
</DOC>